8.3 Local Anesthetic Systemic Toxicity (LAST) & Lipid Emulsion (Intralipid) Resuscitation

Local Anesthetic Systemic Toxicity (LAST) & Lipid Emulsion (Intralipid) Resuscitation

Local Anesthetic Systemic Toxicity (LAST) is a rare but potentially fatal systemic adverse reaction caused by the inadvertent intravascular injection or rapid systemic absorption of local anesthetic agents. LAST affects the central nervous system (CNS) and cardiovascular system (CVS). With the expansion of ultrasound-guided regional anesthesia and high-volume peripheral nerve blocks, perioperative registered nurses must understand the early clinical prodrome, high-risk procedures, and the specific resuscitation protocol utilizing 20% Lipid Emulsion (Intralipid).

---

Pathophysiology of LAST

Local anesthetics exert their therapeutic effect by reversibly binding to voltage-gated sodium ($Na^+$) channels on neuronal cell membranes, inhibiting inward sodium influx and blocking action potential conduction. However, when toxic systemic plasma concentrations are reached, local anesthetics non-selectively block voltage-gated sodium, potassium, and calcium channels in cardiac conduction tissue and cerebral cortex neurons.

Lipophilic amino-amide local anesthetics—specifically bupivacaine, levobupivacaine, and ropivacaine—possess high tissue binding affinity and slow dissociation kinetics, making them significantly more cardiotoxic than less lipophilic agents like lidocaine or mepivacaine.

CNS vs. Cardiovascular Sensitivity

Central nervous system neurons are exquisitely sensitive to local anesthetic toxicity. Consequently, CNS excitation and depression typically precede cardiovascular collapse. However, with bupivacaine, cardiac arrest can occur simultaneously with or immediately following initial symptoms without preceding classic CNS warning signs.

---

Clinical Progression & Symptoms

The clinical presentation of LAST follows a progressive spectrum across CNS and cardiovascular systems:

---

High-Risk Procedures & Patient Risk Factors

High-Risk Injection Sites

LAST risk correlates directly with tissue vascularity and total anesthetic dose. Injection sites with highest systemic absorption rates include:

1. Intercostal nerve blocks (highest vascular absorption rate)
2. Caudal & Epidural blocks
3. Brachial plexus blocks (interscalene, supraclavicular)
4. Abdominal wall blocks (transversus abdominis plane - TAP, fascia iliaca)

Patient Risk Factors

• Age Extremes: Neonates, infants, and elderly patients have reduced plasma protein levels (alpha-1 acid glycoprotein) and impaired hepatic clearance.
• Organ Dysfunction: Severe hepatic dysfunction (decreased amide metabolism) or renal impairment (reduced clearance).
• Cardiac Disease: Pre-existing heart failure, conduction defects, or ischemic heart disease increase susceptibility to cardiotoxicity.

---

Lipid Emulsion (Intralipid 20%) Resuscitation Protocol

Intravenous Lipid Emulsion (20% Intralipid) is the specific antidote for LAST. It functions via the "Lipid Sink" Theory: lipid molecules form an intravascular lipid compartment that extracts lipophilic local anesthetic molecules from cardiac and brain cell membranes back into the vascular space, accelerating clearance and restoring organ function. Lipid emulsion also exerts direct cardiotonic and metabolic effects on cardiac myocytes.

[1. Call LAST Emergency & Lipid Kit] ➔ [2. Secure Airway 100% O2] ➔ [3. Control Seizures (Benzos)]
                                                                           │
[6. Post-Resuscitation ICU Care] ◄── [5. Modified ACLS Epinephrine] ◄── [4. Intralipid 20% Bolus + Infusion]

Dosing & Administration Schedule (20% Lipid Emulsion)

• Initial Bolus: Administer 1.5 mL/kg IV over 1 minute (approx. 100 mL bolus for a 70 kg adult).
• Continuous Infusion: Immediately start a continuous IV infusion at 0.25 mL/kg/min (approx. 18 mL/min for a 70 kg adult).
• Repeat Boluses: If cardiovascular stability is not restored or hemodynamic collapse recurs, repeat the 1.5 mL/kg IV bolus once or twice every 3–5 minutes.
• Infusion Escalation: Double the infusion rate to 0.50 mL/kg/min if blood pressure remains low.
• Maximum Total Dose: 12 mL/kg total volume over the first 30 minutes of resuscitation.
• Duration: Continue lipid infusion for at least 10–15 minutes after hemodynamic stability is fully restored.

---

Resuscitation & ACLS Modifications in LAST

Standard Advanced Cardiovascular Life Support (ACLS) protocols must be modified during LAST resuscitation:

1. Airway Management: Administer 100% oxygen. Hyperventilate the patient to prevent hypoxia, hypercarbia, and metabolic acidosis. Acidosis increases the unbound free fraction of local anesthetic, worsening toxicity.
2. Seizure Control: Treat seizures promptly with benzodiazepines (e.g., midazolam 1–2 mg IV). Avoid propofol in hemodynamically unstable patients, as propofol worsens cardiac depression.
3. Modified Epinephrine Dosing: Reduce individual epinephrine boluses to $\le 1\ \mu\text{g/kg}$ IV (e.g., 10 to 100 mcg IV doses instead of the standard 1 mg ACLS dose). Standard 1 mg epinephrine doses impair lipid-mediated reversal and trigger refractory ventricular arrhythmias.
4. Medications to Avoid: Avoid vasopressin, calcium channel blockers, beta-blockers, and procainamide (class Ia antiarrhythmics exacerbate sodium channel blockade).

---

Key Exam Traps & Clinical Pitfalls

⚠️ Exam Trap: Never attempt to use Propofol as a substitute for 20% Lipid Emulsion! Although propofol is formulated in a lipid emulsion, the lipid content is insufficient and the drug causes severe, fatal myocardial depression.

⚠️ Exam Trap: Never give standard 1 mg ACLS Epinephrine boluses during LAST cardiac arrest—reduce epinephrine doses to $\le 1\ \mu\text{g/kg}$ IV (10–100 mcg).

⚠️ Exam Trap: Do not delay Intralipid administration until full cardiac arrest occurs; give Intralipid at the first sign of systemic toxicity, severe arrhythmias, or seizures.